JYJunji Yamaguchi

Junji Yamaguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junji Yamaguchi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dementia With Severe Psychiatric Symptoms Complicated by Family Neglect Treated via Home‐Visit Treatment: A Case Report

    by Junji Yamaguchi, Ryoichi Sadahiro, Hiromichi Matsuoka

    Barriers to necessary hospitalization can be significant in clinically complex cases involving family neglect and severe psychiatric symptoms. Home‐visit treatment with interprofessional collaboration may be an effective intervention, helping establish relationships with the patient and family, increasing awareness of the illness, and facilitating appropriate hospital care when needed.

  • Open Access

    Zolpidem Withdrawal Delirium Developed as Severe Psychiatric and Physical Symptoms in a Patient With a History of Ovarian Cancer: A Case Report and Literature Review

    by Junji Yamaguchi, Ryoichi Sadahiro, Saho Wada, Eri Nishikawa, Tatsuto Terada, Rika Nakahara, Hiromichi Matsuoka

    Background: Zolpidem is a common medication for sleep disorders prescribed during or after cancer treatment. However, the possible risk of zolpidem withdrawal delirium does not seem to be well recognized by medical staff engaged in cancer treatment. Case Presentation: A female in her 50s with a diagnosis of ovarian cancer underwent bilateral oophorectomy 6 years earlier. No recurrence was observed after treatment with anticancer drugs. She had been prescribed zolpidem (10 mg/day, oral) by her attending physician for approximately 5 years, although she often took it 2–3 times the dose when her insomnia was severe. At X years, she was hospitalized due to abdominal pain from infectious enteritis, and zolpidem was discontinued. On Day 3 of hospitalization, however, she became extremely confused and disoriented with psychomotor agitation, delusions, and myoclonus. Laboratory findings, brain magnetic resonance imaging (MRI), and spinal fluid examination denied encephalitis and encephalopathy. Finally, the patient was diagnosed with zolpidem withdrawal delirium, and lemborexant was effective for her sleep disorders. She was discharged on Day 22 with no aftereffects. Conclusions: Cancer patients might be relatively more prone to zolpidem withdrawal delirium because of the possible Blood–Brain Barrier dysfunction derived from anticancer drug treatment or cancer. Oncologists and liaison psychiatrists need to prevent and detect zolpidem withdrawal delirium because it may be difficult to manage withdrawal delirium with severe psychiatric symptoms in cancer hospitals with no dedicated psychiatric ward.

  • Open Access

    Organic Psychosis due to Lung Cancer Metastasis Accompanied by Severe Psychiatric Symptoms Treated With Blonanserin Transdermal Patch: A Case Report and Literature Review

    by Junji Yamaguchi, Ryoichi Sadahiro, Saho Wada, Eri Nishikawa, Tatsuto Terada, Rika Nakahara, Hiromichi Matsuoka

    Background: Organic psychosis associated with brain metastasis from cancer occasionally presents with psychiatric symptoms such as delusions or violent behavior. In these cases, however, psychotropics may not be sufficiently effective, and their continuous use may also be difficult due to side effects. Besides, regular oral administration of psychotropics becomes more difficult when medication refusal develops. Case Presentation: A man in his 80s. At X‐1 years, lung cancer was found to have metastasized to the right frontal lobe, with no apparent psychiatric symptoms. At X years, however, the patient was hospitalized because of consciousness disturbance, and new brain metastases in the right parietal and occipital lobes were detected. Irritability, violent behaviors, and delusions became dominant and required physical restraint. Refusal to take oral medications was also noted. Blonanserin transdermal patch (40 mg/day) was started along with an intravenous drip of haloperidol, and he became mentally calm, although psychiatric symptoms persisted with fluctuations. His mental status was finally stabilized with blonanserin transdermal patch (80 mg/day) with no side effects, leading to hospital discharge on Day 53 after admission. Conclusions: Blonanserin transdermal patch may be effective for organic psychosis associated with brain metastasis. Because it can be used in cases where oral medication is difficult and has relatively few side effects, such as hypotension and extrapyramidal symptoms, it may be a helpful option for oncologists and liaison psychiatrists.

  • Open Access

    Potential Effectiveness of Yokukansan and Lemborexant as Alternative Candidates to Benzodiazepines to Prevent Benzodiazepine Withdrawal Delirium in the Cancer Perioperative Period: A Case Report and Literature Review

    by Junji Yamaguchi, Ryoichi Sadahiro, Saho Wada, Eri Nishikawa, Tatsuto Terada, Rika Nakahara, Hiromichi Matsuoka

    Background: Benzodiazepine withdrawal delirium is a serious problem, and several candidates have been proposed to manage benzodiazepine withdrawal, such as valproic acid and carbamazepine, up to now. However, it is not always possible to use these candidates during the cancer perioperative period due to the risk of oversedation, and new candidates are being awaited. Case Presentation: A woman in her late 80s was prescribed lorazepam 1.0 mg/day and brotizolam 0.25 mg/day for persistent anxiety and insomnia following the death of her husband and son. She had been receiving these medications for 3 years; however, they were ineffective, and she began consuming double the prescribed dose to manage her symptoms. Additionally, problematic drinking behavior was also acknowledged. Three months before the cancer surgery, the first author and her primary physician collaborated; lorazepam was gradually reduced to 0.5 mg/day, while yokukansan (5.0 g/day) and lemborexant (5.0 mg/day) were introduced instead. Her mental status stabilized, and surgery was performed as planned with no adverse effects. Postoperative and benzodiazepine withdrawal delirium were not observed. Conclusion: The combination of yokukansan and lemborexant may be an effective replacement for benzodiazepines in terms of their effects on 5‐hydroxytryptamine‐related mechanisms and regulation of the sleep cycle. During the cancer perioperative period, physicians may consider the gradual replacement or reduction of benzodiazepines with yokukansan and lemborexant before the surgery to avoid possible benzodiazepine‐related delirium.

  • Open Access

    Consciousness disturbance due to lithium carbonate intoxication developed in a patient with cancer and bipolar affective disorder: A case report and literature review

    by Junji Yamaguchi, Ryoichi Sadahiro, Saho Wada, Eri Nishikawa, Tatsuto Terada, Rika Nakahara, Hiromichi Matsuoka

    Background: Patients with comorbid cancer and bipolar affective disorder require psychiatric symptom stabilization to continue cancer treatment, and mood stabilizers, including lithium carbonate, are often administered during cancer treatment. However, the risk of lithium carbonate‐induced consciousness disturbance seems not to be well recognized among medical professionals involved in cancer treatment.Case Presentation: A woman in her 70s was diagnosed with bipolar affective disorder at approximately 28 years of age and was hospitalized twice for worsening manic depressive episodes. Lithium carbonate (600 mg/day, orally) was administered. At X‐3 years, she was diagnosed with left breast cancer (cT2N2M0, Stage IIIA) and received preoperative chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) following total mastectomy and axillary lymph node dissection. At X years, she was hospitalized because of a consciousness disturbance. Brain metastasis and lithium carbonate overdose were eliminated, and renal function was normal. However, the blood lithium level was 1.74 mEq/L, and lithium carbonate intoxication due to dehydration was most suspected. Her level of consciousness improved with adequate intravenous fluid, and she recovered with no adverse effects.Conclusions: In patients with comorbid cancer and bipolar affective disorder, the stabilization of psychiatric symptoms is necessary, and lithium carbonate is an important medication. However, oncologists and liaison psychiatrists need to consider the possible risk of consciousness disturbance due to lithium carbonate intoxication.

  • Open Access

    Development of cefepime‐induced encephalopathy in a patient with depression and rectal cancer: A case report

    by Junji Yamaguchi, Ryoichi Sadahiro, Saho Wada, Eri Nishikawa, Tatsuto Terada, Rika Nakahara, Hiromichi Matsuoka

    Background: Cefepime, a fourth‐generation cephalosporin, has neurotoxic side effects such as encephalopathy. Baseline conditions, including blood–brain barrier (BBB) impairment and renal dysfunction, are known to associate with elevated central nervous concentration of cefepime. Although BBB dysfunction occurs with depression or cancer, currently, neither is regarded as a risk factor for cefepime‐induced encephalopathy. Case Presentation: A 79‐year‐old woman with a history of depression and rectal cancer was hospitalized for a bacterial liver abscess. Brain metastasis and other causes for delirium were excluded, and no renal dysfunction was observed. However, 11 days after cefepime and metronidazole administration, the patient suddenly developed confusion, disorientation, and myoclonus, with no apparent changes on brain magnetic resonance imaging. Electroencephalography revealed a consistent tri‐phasic wave pattern. Clinical symptoms were well consistent with cefepime‐induced encephalopathy; hence, cefepime and metronidazole were discontinued, followed by rapid physical and mental recovery, with no aftereffects. Conclusions: In terms of BBB dysfunction, depression and cancer might be possible occult risk factors for cefepime‐induced encephalopathy. Doctors need to pay attention to encephalopathy risk when administering cefepime in patients with depression or cancer because the psychiatric symptoms of encephalopathy, depression, and delirium from other causes are often confusing, leading to misdiagnosis and a poor prognosis.


  • Open Access

    A case report of benzodiazepine withdrawal delirium due to accidental discontinuation of benzodiazepines in cancer perioperative period

    by Junji Yamaguchi, Ryoichi Sadahiro, Saho Wada, Eri Nishikawa, Tatsuto Terada, Rika Nakahara, Hiromichi Matsuoka

    Background: Benzodiazepines are known for their possible risk of delirium, especially when administered to older adults or during the perioperative period. However, the risk of sudden discontinuation of benzodiazepines and subsequent withdrawal delirium seems to be underappreciated and not properly recognized in cancer treatment, even among healthcare workers.Case Presentation: A man in his late 70s was diagnosed with rectal cancer and had a history of taking etizolam and alprazolam for over 15 years. After hospitalization for cancer, these benzodiazepines were discontinued abruptly 2 days before the surgery, due to concerns about benzodiazepine‐related delirium. After half a day, severe benzodiazepine withdrawal symptoms, such as disorientation, agitation, tachycardia, diaphoresis, and muscle twitching, appeared. The patient was diagnosed with delirium associated with benzodiazepine withdrawal, and his symptoms subsided soon after re‐administration of benzodiazepines. Despite development of mild postoperative delirium, the operation was performed safely.Conclusion: The rapid and abrupt discontinuation of benzodiazepines before cancer surgery could impose a high risk of benzodiazepine withdrawal delirium in patients, which makes the management of psychiatric symptoms in the perioperative period more complex and difficult. We believe that it is necessary to highlight the risks of withdrawal delirium and abrupt benzodiazepine discontinuation in cancer treatment. Moreover, re‐education on this topic is essential for healthcare workers.


  • Open Access

    Severe behavioral and psychological symptoms of dementia successfully treated at home with a blonanserin transdermal patch: A case report

    by Junji Yamaguchi, Ryoichi Sadahiro, Takatoshi Hirayama, Saho Wada, Rika Nakahara, Hiromichi Matsuoka

    Aim: Behavioral psychological symptoms of dementia (BPSD) are sometimes difficult to treat due to severe psychiatric symptoms such as delusions of poisoning and violent behavior. Moreover, in cases of parental neglect, the management of these psychiatric symptoms becomes more difficult. Therefore, home‐visiting doctors sometimes have to manage patients with BPSD and severe psychiatric symptoms, and a new approach is needed. In this case report, the effect of blonanserin transdermal patch on these patients is to be highlighted.Methods: The patient is a 91‐year‐old woman diagnosed with Alzheimer's disease. She had severe BPSD such as delusion of robbery and violent behavior, and refused oral medications including memantine and yokukansan. Then she was treated with blonanserin transdermal patch (20 mg/day). The severity of psychiatric symptoms of BPSD was assessed over time using the Neuropsychiatric Inventory (NPI) score. Moreover, the patient's cognitive function was also assessed over time by Mini‐Mental State Examination (MMSE).Results: After the introduction of blonanserin patch, the patient's psychiatric symptoms were stabilized markedly, and both NPI and MMSE scores improved. The patient was able to stay at home calmly and was mentally well stabilized to the extent that she did not require hospitalization. No apparent side effects were admitted.Conclusions: The blonanserin transdermal patch may be able to manage BPSD at home and is effective in patients who refuse oral medications. Home‐visiting doctors may consider the use of blonanserin patches at home for patients with severe BPSD, manifesting as delusions of poisoning and refusing oral drugs.


  • Open Access

    Delirium due to Trousseau syndrome treated with memantine and perospirone: A case report

    by Junji Yamaguchi, Takatoshi Hirayama, Ryoichi Sadahiro, Rika Nakahara, Hiromichi Matsuoka

    Background: Trousseau syndrome is a hypercoagulability syndrome associated with cancer. It is known that delirium occasionally occurs after the onset of Trousseau syndrome. However, there have been no detailed reports about treatment for psychiatric symptoms of delirium associated with Trousseau syndrome.Case Presentation: A 61‐year‐old man with lung cancer was hospitalized due to Trousseau syndrome. Delirium occurred after hospitalization and psychiatric symptoms worsened. Although haloperidol, risperidone, and chlorpromazine were used, severe insomnia persisted. After memantine (5 mg/day) was used with perospirone, the patient's psychiatric symptoms gradually decreased; he could sleep for 4–5 h at night. Due to psychiatric improvement, he was able to return home and resume immunotherapy for lung cancer as scheduled.Conclusion: We report the first case of Trousseau syndrome delirium treated by memantine used with perospirone. Although further studies are needed, memantine and perospirone might be candidates for the management of psychiatric symptoms associated with Trousseau syndrome.